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Abstract  
Lipodystrophy is a rare syndrome characterized by loss of adipose tissue, insulin 
resistance, hypertriglyceridemia, steatohepatitis, splenomegaly, acanthosis nigricans 
and cardiomyopathy. It can be congenital or acquired with partial or generalized 
involvement. The most frequent cardiac finding is that of an hypertrophic symmetric 
cardiomyopathy which progresses with age. We describe here a case of a young man 
with generalized lipodystrophy who came to our cardiovascular magnetic resonance 
(CMR) laboratory to assess cardiac involvement. CMR showed a focal area of 
hypertrophy involving the basal anterior septum and basal anterior free wall, with normal 
wall thickness of remaining left ventricle segments. There was also an intramyocardial 
area of late gadolinium enhancement with the same distribution, with no evidence for 
myocardial edema and/or fatty infiltration at the same level. No left ventricular outflow 
tract obstruction was found. To our knowledge this is the first reported case of 
asymmetric hypertrophic cardiomyopathy in generalized lipodystrophy fully 
characterized by CMR. The mechanisms underlying the cardiomyopathy in this disease 
are still unclear.  
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Introduction 
Lipodystrophy is a rare syndrome characterized by loss of adipose tissue, with typical  
persistence of fat in certain anatomical regions such as buccal region, tongue, palm of 
the hand and sole of the foot.1 The etiology may be congenital (with an autosomal 
recessive pattern) or acquired and the involvement can be partial or generalized.2 Other 
clinical features may include insulin resistance, hypertriglyceridemia, steatohepatitis, 
acanthosis nigricans, splenomegaly, acromegaloid features and cardiomyopathy.  
Cardiac abnormalities associated with lipodystrophy may range from incidental 
evidence of asymptomatic cardiomyopathy, with hypertrophic phenotype (more often 
with a diffuse left ventricular involvement) or with dilated phenotype, up to severe heart 
failure symptoms.3,4 In this condition, the underlying mechanisms of cardiomyopathy are 
still unclear, but the cardiac involvement seems to be associated with a poor prognosis.4  
We report here a case of generalized lipodystrophy with evidence of asymmetric 
hypertrophic cardiomyopathy.   
 
Case Report     
The patient is a male subject diagnosed with generalized lipodystrophy at birth because 
of severe lipoatrophy and acanthosis nigricans involving the skin of axillae and groin. He 
was then referred to pediatric outpatient clinic for periodic follow-up and the diagnosis 
was confirmed during the growth. Since the age of 10 months abdominal ultrasound 
showed hepatic steatosis with hepatosplenomegaly and a 3/6 systolic murmur was 
noted. During puberty, echocardiography showed asymmetric hypertrophic 
cardiomyopathy involving the interventricular septum with no left ventricular outflow tract 
obstruction and mild mitral regurgitation. His blood pressure values have consistently 
been within normal ranges. ECG showed Q waves in the precordial leads. At the age of 
17, esophagogastroduodenoscopy evidenced the presence of esophagus varices and 
treatment with propranolol was established. Laboratory results showed impaired fasting 
glucose, thrombocytopenia and mild hypertriglyceridemia. At the age of 30, ECG 
showed inverted T waves in precordial leads and echocardiography confirmed left 
ventricular hypertrophy confined to the interventricular septum. He was then referred to 
our CMR laboratory at a time when the phenotype of a generalized lipodystrophy was 
evident (Figure 1).   
CMR images were acquired with a 1,5 Tesla scanner equipped with a multi-element 
phased-array cardiac coil. Scout images confirmed the general lack of subcutaneous 
and visceral adipose tissue (Figure 2). The cardiac imaging protocol included the 
acquisition of a series of cine SSFP images, dark-blood FSE T1-weighted and STIR T2-
weighted images, and late post-contrast T1-weighted images (acquired 10-15 min after 
the injection of a bolus of gadobenate dimeglumine; 0.10 mmol/kg) in standard cardiac 
views. At the left ventricular level, CMR showed normal regional and global systolic 
function (ejection fraction = 71%), an increased global indexed mass (130 gr/m2) and 
myocardial hypertrophy limited to the basal anterior septum and the contiguous anterior 
free wall (maximum end-diastolic wall thickness = 22 mm; Figure 3). The remaining left 
ventricular segments showed normal values of wall thickness. In the same 
anterior/antero-septal region, the demonstration of an hypointense signal on pre-
contrast dark-blood images was not compatible with the presence of myocardial edema 
and/or fatty infiltration (Figure 4). Instead, post-contrast images revealed a distinct focal 
area of late gadolinium enhancement in the hypertrophied region of the left ventricle as 
a possible marker of myocardial fibrosis/necrosis (Figure 5). Left atrium was dilated, no 
significant mitral valve regurgitation was detected and no left ventricular outflow tract 
obstruction was found.  
 
Discussion 
Lipodystrophies are a rare group of diseases characterized by generalized or partial 
lipoatrophy, the former affecting all fat deposits, with the latter sparing visceral fat and 
adipose tissue in the upper part of the body.2 They can be due to genetic or acquired 
causes, and the loss of adipose tissue leads to severe metabolic alterations such as 
insulin resistance, low leptin levels with increased appetite, hypertriglyceridemia, and fat 
deposits in lymphoreticular tissues. Cardiac abnormalities have been described since 
1959 in the context of congenital generalized lipodystrophy, but they have not been 
noted in partial lipodystrophies such as the Dunnigan-type.1 The most frequent cardiac 
abnormality is symmetric hypertrophic cardiomyopathy, typically seen in patients with 
mutations involving the gene encoding for seipin which is important for fat biosynthesis.3 
Additional cardiac abnormalities described in the literature are marked autonomic 
disfunction and dilated cardiomyopathy with severe heart failure.3-5 The pathophysiology 
of the cardiomyopathies remains unclear, but it does not appear to be linked to the 
development of hypertension, as this is a rather unusual finding in patients with 
lipodystrophy.  
From a theoretical standpoint, the insulin resistance typically observed in these patients 
may prompt cardiomyocyte hypertrophy by activating insulin-like growth factor (IGF)-1 
receptors, which are largely expressed in the myocardial tissue and stimulate cell 
growth.6 A magnetic resonance spectroscopy and imaging study found that myocardial 
triglyceride content was elevated in hypertrophied cardiomyocytes of patients affected 
by generalized lipodystrophy.7 These findings suggest that triglyceride deposit might 
cause a “lipotoxic cardiomyopathy”, as exceeding lipids are shunted into non-oxidative 
pathways with the accumulation of toxic lipid species.8 This may alter, in turn, cellular 
signaling, promoting mithocondrial dysfunction and cell apoptosis.  
Asymmetric left ventricular hypertrophy has been reported only in few cases, involving 
young patients with lipodystrophy.9 It may possibly be consequence of the 
hyperinsulinaemia-induced overgrowth of an otherwise healthy heart, finally resulting in 
disproportionate thickening of the interventricular septum.10 To our knowledge this is the 
first case with complete CMR tissue characterization of an asymmetric left ventricular 
hypertrophy observed in an adult affected by generalized lipodystrophy. The patient had 
evidence of a focal area of cardiac hypertrophy involving the basal anterior septum and 
anterior free wall, with normal wall thickness of the remaining left ventricular segments. 
There was also a limited area of late gadolinium enhancement with the same regional 
distribution, indicating myocardial tissue damage (potentially myocardial 
fibrosis/necrosis). This is a highly intriguing finding, as asymmetric hypertrophy with late 
gadolinium enhancement involving the hypertrophied segment has been repeatedly 
described in patients with sarcomeric hypertrophic cardiomyopathies and, recently, has 
been linked to an adverse prognosis.11,12 In this specific case, pre-contrast dark blood 
images helped to rule out the presence of edema or fatty infiltration in the hypertrophic 
segments, while the observed area of signal hypointensity on both T1- and T2-weighted 
images could be indicative of reduced cellularity or tissue colliquation.  
In conclusion, in this case describing a patient with generalized lipodystrophy, CMR 
imaging was used to assess cardiac involvement with tissue characterization and 
documented asymmetric non-obstructive left ventricular hypertrophy with a distinct area 
of late gadolinium enhancement. Our findings might help shedding new light on the yet 
mysterious pathophysiology of the cardiac involvement that, when detected in a patient 
with lipodystrophy, is considered to be associated with poor prognosis. However, more 
studies are needed to better characterize the big range of cardiac abnormalities that can 
occur in these rare diseases.  
 
  
References 
1. Seip M. Lipodystrophy and gigantism with associated endocrine manifestations. A new 
diencephalic syndrome? Acta Paediatr. 1959; 48:555–574. 
2. Vigouroux C, Caron-Debarle M, Le Dour C, Magré J, Capeau J. Molecular mechanisms 
of human lipodystrophies: from adipocyte lipid droplet to oxidative stress and 
lipotoxicity. Int J Biochem Cell Biol. 2011;43(6):862-76.  
3. Faria CA, Moraes RS, Sobral-Filho DC, Rego AG, Baracho MF, Egito ES, Brandão-
Neto J. Autonomic modulation in patients with congenital generalized lipodystrophy 
(Berardinelli-Seip syndrome). Europace. 2009;11(6):763-9. 
4. Lupsa BC1, Sachdev V, Lungu AO, Rosing DR, Gorden P. Cardiomyopathy in 
congenital and acquired generalized lipodystrophy: a clinical assessment. Medicine. 
2010;89(4):245-50. 
5. Khalife WI1, Mourtada MC, Khalil J. Dilated cardiomyopathy and myocardial infarction 
secondary to congenital generalized lipodystrophy. Tex Heart Inst J. 2008;35(2):196-9. 
6. Gomes KB, Pardini VC, Fernandes AP. Clinical and molecular aspects of Berardinelli-
Seip Congenital Lipodystrophy (BSCL). Clin Chim Acta. 2009;402(1-2):1-6. 
7. Nelson MD, Victor RG, Szczepaniak EW, Simha V, Garg A, Szczepaniak LS. Cardiac 
steatosis and left ventricular hypertrophy in patients with generalized lipodystrophy as 
determined by magnetic resonance spectroscopy and imaging. Am J Cardiol. 2013 
1;112(7):1019-24. 
8. Wende AR1, Abel ED. Lipotoxicity in the heart. Biochim Biophys Acta. 
2010;1801(3):311-9.  
9. Bhayana S, Siu VM, Joubert GI, Clarson CL, Cao H, Hegele RA. Cardiomyopathy in 
congenital complete lipodystrophy. Clin Genet. 2002;61(4):283-7. 
10. Friguls B, Coroleu W, del Alcazar R, Hilbert P, Van Maldergem L, Pintos-Morell G. 
Severe cardiac phenotype of Berardinelli-Seip congenital lipodystrophy in an infant with 
homozygous E189X BSCL2 mutation. Eur J Med Genet. 2009;52(1):14-6. 
11. Maron MS, Maron BJ, Harrigan C, Buros J, Gibson CM, Olivotto I, Biller L, Lesser JR, 
Udelson JE, Manning WJ, Appelbaum E. Hypertrophic cardiomyopathy phenotype 
revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol. 
2009 Jul 14;54(3):220-8.  
12. Rubinshtein R, Glockner JF, Ommen SR, Araoz PA, Ackerman MJ, Sorajja P, Bos JM, 
Tajik AJ, Valeti US, Nishimura RA, Gersh BJ. Characteristics and clinical significance of 
late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in 
patients with hypertrophic cardiomyopathy. Circ Heart Fail. 2010 Jan;3(1):51-8. 
  
Figure legend  
Figure 1: Patient's phenotype showing the features of a thin young man with an 
acromegaloid appearance and lack of subcutaneous fat. 
Figure 2: Coronal scout image confirming the absence of subcutaneous and visceral 
adipose tissue; severe spine scoliosis is also noted. 
Figure 3: Focal hypertrophy (arrow) of the basal anterior septum and the contiguous 
anterior free wall as seen on short-axis view (A.) and 3-chamber view (B.) on SSFP 
imaging. 
Figure 4: Pre contrast dark blood images with FSE T1-weighted technique (A.)  and 
STIR T2-weighted technique (B.), both showing a hypointense area (arrow) in the 
hypertrophic anterior/antero-septal region excluding, respectively, the presence of fatty 
infiltration and edema.  
Figure 5: Late post-contrast images in short-axis view (A.) and modified 2-chamber 
view (B.) showing a focal area of late gadolinium enhancement (arrow) involving the 
hypertrophic anterior/antero-septal region and suggestive of myocardial 
fibrosis/necrosis. 
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